Composition for the treatment of arthritis containing a dibenzo-p-dioxin derivative as the active ingredient

Abstract

Disclosed is a composition for treating arthritis containing a dibenzo-p-dioxin derivative as an active ingredient. This dibenzo-p-dioxin derivative is very effective in inhibiting NF-kB and AP-1 activity, alleviates the symptoms of degenerative arthritis and rheumatoid arthritis without irritating the skin or causing side effects, and can continue to exhibit improvement effects for a considerable period of time after discontinuation of treatment. Additionally, when the dibenzo-p-dioxin derivative is contained in liposomes, the composition of the invention exhibits much greater effects on treating arthritis by absorption through skin, and thus is useful for the treatment of degenerative arthritis and rheumatoid arthritis.

1 . A composition for treating arthritis, containing, as an active ingredient, one or more selected from the group consisting of dibenzo-p-dioxin derivatives of Formulas 1 to 10 below: 
       
         
           
           
               
               
           
         
         
           
           
               
               
           
         
         
           
           
               
               
           
         
         
           
           
               
               
           
         
         wherein each R is independently hydrogen, C 1 ˜C 4  alkyl, C 2 ˜C 10  alkenyl, phenyl, hydroxyphenyl, dihydroxyphenyl, phenyl-C 1 ˜C 4  alkyl or R′(C═O) in which R′ is C 1 ˜C 4  alkyl or C 2 ˜C 20  alkenyl. 
       
     
     
         2 . The composition according to  claim 1 , wherein each R in Formulas 1 to 10 is independently hydrogen, methyl, acetyl or oleoyl. 
     
     
         3 . The composition according to  claim 1 , wherein each R in Formulas 1 to 10 is independently hydrogen. 
     
     
         4 . The composition according to  claim 1 , wherein the composition comprises a combination of two or more compounds selected from the group consisting of 0.1˜10 wt % of a compound of Formula 1, 1˜60 wt % of a compound of Formula 2, 1˜20 wt % of a compound of Formula 3, 0.2˜20 wt % of a compound of Formula 4, 0.3˜30 wt % of a compound of Formula 5, 0.3˜30 wt % of a compound of Formula 6, 0.1˜10 wt % of a compound of Formula 7, 0.1˜10 wt % of a compound of Formula 8, 0.1˜10 wt % of a compound of Formula 9 and 0.2˜20 wt % of a compound of Formula 10. 
     
     
         5 . The composition according to  claim 1 , wherein the dibenzo-p-dioxin derivatives of Formulas 1 to 10 are extracted and separated from one or more selected from the group consisting of  Eisenia bicyclis, Eisenia arborea, Eisenia desmarestioides, Eisenia galapagensis, Eisenia masonii, Ecklonia kurome, Ecklonia cava, Ecklonia stolonifera, Ecklonia maxima, Ecklonia radiata, Ecklonia bicyclis, Ecklonia biruncinate, Ecklonia buccinalis, Ecklonia caepaestipes, Ecklonia exasperta, Ecklonia fastigiata, Ecklonia brevipes, Ecklonia arborea, Ecklonia latifolia, Ecklonia muratii, Ecklonia radicosa, Ecklonia richardiana  and  Ecklonia wrightii.    
     
     
         6 . The composition according to  claim 1 , wherein the composition contains 0.2˜2 wt % of the dibenzo-p-dioxin derivative based on total weight of the composition. 
     
     
         7 . The composition according to  claim 1 , wherein the arthritis is degenerative arthritis or rheumatoid arthritis. 
     
     
         8 . The composition according to any one of  claims 1  to  7 , wherein the composition is prepared in a form of a skin external-use formulation, including an ointment, lotion, cream, gel, skin emulsion, skin suspension, patch or spray. 
     
     
         9 . The composition according to any one of  claims 1  to  7 , wherein the composition is prepared in a form of a liposome formulation using a liposome.